A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Akeso
Merck Sharp & Dohme LLC
OncoSil Medical Limited
Novartis
FBD Biologics Limited
Taiho Oncology, Inc.
AbbVie
Revolution Medicines, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Akeso
Bristol-Myers Squibb
Pfizer
Toray Industries, Inc
CARsgen Therapeutics Co., Ltd.
US Oncology Research
Pfizer
Ono Pharmaceutical Co. Ltd
Actuate Therapeutics Inc.